Hepion provides pipeline update: Rencofilstat Phase 2a NASH trial positive; Phase 2b and HCC trials underway

Hepion Pharmaceuticals, Inc.

Phase 2a NASH trial (AMBITION) met safety endpoints; showed ALT and Pro-C3 reductions over 28 days.
Cash $98.7M as of Sept 30, 2021; 76.2M shares outstanding.
Phase 2b NASH trial (ASCEND-NASH) to randomize 336 subjects across 75, 150, 225 mg doses for 12 months.
Phase 2a HCC trial (HEPA-RENCOFILSTAT-209) launched with Simon 2-stage design; primary endpoint disease control rate.
AI-POWR platform predicts responders; transcriptomics misclassification error <5% in Phase 2a analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.